29 C
Vientiane
Thursday, June 19, 2025
spot_img
Home Blog Page 410

Fosun International Ranked Top 1% in S&P Global’s Sustainability Yearbook 2025 (China Edition) for the Second Consecutive Year

HONG KONG, April 17, 2025 /PRNewswire/ — On 15 April 2025, S&P Global published the Sustainability Yearbook 2025 (China Edition). Fosun International Limited (HKEX stock code: 00656, “Fosun International”) was successfully included in S&P Global’s Sustainability Yearbook 2025 (China Edition) and was ranked top 1% for the second consecutive year, recognizing its continuous efforts in environmental, social and governance (ESG) over the years.

S&P Global has published its Sustainability Yearbook (China Edition) for the third consecutive year, aiming to distinguish and recognize individual Chinese companies, within their industries, that have demonstrated strengths in corporate sustainability based on S&P Global’s Corporate Sustainability Assessment (CSA).

This year, more than 1,600 Chinese companies assessed for the CSA were considered for inclusion in the S&P Global’s Sustainability Yearbook 2025 (China Edition). Among these companies, S&P Global identified the top performing companies in each industry and excluded some companies according to the established rules. In the end, around 160 companies with the best performance were listed in this Yearbook. To be listed in the Yearbook, companies must score within the top 15% of their industry. In addition, only companies within each industry, with a minimum CSA score of 60 and have a score that within 1% of the industry’s top-performing company can be ranked top 1% in the Yearbook.

Building on years of dedicated efforts in the ESG field, Fosun International achieved an impressive score of 70 in the 2024 S&P Global CSA, maintaining its leading position in the industry and surpassing the industry average by approximately 40 points.

As of April 2025, Fosun International ranks among the top 5% of global peers participating in the CSA and has been successfully included in S&P Global’s Sustainability Yearbook 2025.

In recent years, Fosun International has consistently achieved excellent results in global ESG ratings. As of now, Fosun International’s MSCI ESG rating has remained AA since 2021. It received an HSI ESG rating of AA- and has been included in the Hang Seng Corporate Sustainability Benchmark Index for years. Furthermore, Fosun International’s FTSE Russell ESG score was consistently higher than the global industry average and it has been continuously selected as a constituent stock of the FTSE4Good Index Series.

Fosun has always paid attention to the development and impact of global sustainability. It has established a sound ESG management system and integrated ESG requirements into its business management over the years. Fosun has actively leveraged its innovation and global operational strengths to address critical social issues. It has long been dedicated to philanthropy projects in areas such as rural revitalization, healthcare, educational equity, community construction, culture and art, significantly expanding its impact across global communities.

Looking ahead, Fosun will continue to deepen its core businesses, strengthen innovation, and drive globalization, promoting the long-term sustainable development of its business. By creating lasting value for all stakeholders, Fosun remains committed to fulfilling its mission of “Creating happier lives for families worldwide”.

LG Expands Advanced Materials Business Globally With LG PuroTec

Company Showcases Anti-fungal and Antibacterial Glass Powder to Global B2B Customers

SEOUL, South Korea, April 17, 2025 /PRNewswire/ — LG Electronics (LG) is accelerating the global expansion of its advanced materials business with LG PuroTecTM, an antimicrobial glass powder designed for diverse B2B applications. The company is targeting global markets – including across Asia – with this innovative material that offers antibacterial and anti-fungal properties.

LG showcased its lineup of PuroTec to the international B2B market at Chinaplas 2025.
LG showcased its lineup of PuroTec to the international B2B market at Chinaplas 2025.

At Chinaplas 2025, being held in Shenzhen, Guangdong, China, LG showcased its lineup of PuroTec to the international B2B market. Recognized as one of the world’s leading industrial materials exhibitions, Chinaplas 2025 has brought together over 4,000 companies from around 150 countries to introduce cutting-edge materials across industries such as plastics and rubber.

LG introduced PuroTec's broad B2B applicability through use cases in appliances, construction, medical, and textiles.
LG introduced PuroTec’s broad B2B applicability through use cases in appliances, construction, medical, and textiles.

At the event, LG highlighted the wide applicability of PuroTec to B2B customers, and also introduced diverse use cases in home appliances, construction materials, medical devices and textiles that PuroTec can be applied to.

PuroTec can be blended into materials like plastic, paint and rubber to provide antibacterial and anti-fungal effects that can help prevent odors, contamination and discoloration caused by microorganisms. Even in small quantities, it maintains excellent efficacy and mixes easily with various base materials, enhancing its value across manufacturing sectors.

Building on its long-standing expertise in glass powder technology – originally developed for use in its home appliances – LG is positioning PuroTec as a new pillar of its B2B materials strategy. Since introducing the product in 2023, LG has expanded its presence in Asian markets such as China, Vietnam and India, while securing approximately 420 related patents since 2006.

As part of its global expansion strategy, LG plans to introduce PuroTec in Europe and North America, with a major showcase planned at K 2025 in Düsseldorf, Germany, this October.

In addition to PuroTec, LG continues to invest in the development of advanced materials. A notable example is Marine Glass, a functional, water-soluble glass material designed to help support marine ecosystem restoration. When dissolved, it changes into an inorganic ion state that stimulate the growth of both microalgae and macroalgae – helping to rehabilitate damaged ocean environments.

“We will continue to develop advanced materials that meet the evolving needs of global B2B customers,” said Baek Seung-tae, head of the LG’s Kitchen Solution Business, “These innovative solutions will enable us to expand beyond traditional home appliances and into broader, future-forward industries.”

# # #

About LG Electronics Home Appliance Solution Company 

The LG Home Appliance Solution Company (HS) is a global leader in home appliances and AI home solutions. By leveraging industry-leading core technologies, the HS Company is committed to enhancing consumers’ quality of life and promoting sustainability. The company develops thoughtfully designed kitchen and living appliance solutions and has recently integrated LG’s Robot Business Division to incorporate advanced robot technologies into its home solutions. Together, these products offer enhanced convenience, exceptional performance, efficient operation and sustainable lifestyle solutions. For more news on LG, visit www.LGnewsroom.com.

 

Radisson Hotel Group opens Radisson Resort Mui Ne, a private beachfront paradise on Vietnam’s pristine coast

BRUSSELS, April 17, 2025 /PRNewswire/ — Radisson Hotel Group is pleased to announce the opening of Radisson Resort Mui Ne, a secluded beachfront retreat along the unspoiled shores of Suoi Nuoc Beach in Binh Thuan, Vietnam. Here, clear turquoise waters meet golden sands to create a sanctuary where comfort, sustainability, and natural beauty blend seamlessly for an unforgettable coastal escape.

Radisson Resort Mui Ne Overview
Radisson Resort Mui Ne Overview

The resort features 126 exclusive rooms, including 12 beachfront villas and eight garden villas, all with private pools, catering to a wide range of travelers, from couples to families and groups. The property includes family-friendly amenities such as a dedicated kids club, pet-friendly facilities, and spacious family suites. Guests can enjoy reviving wellness and spa facilities alongside various adventure sports activities, including kite surfing and paddle boarding. The clean lines and natural light reflect the Scandinavian style, beautifully complemented by the rich colors and textures inspired by Phan Thiet and Mui Ne’s landscape and culture.

“Radisson Resort Mui Ne is not just a hotel; it’s a destination where every moment is created to offer unparalleled luxury and adventure,” said Richard Mehr, General Manager of Radisson Resort Mui Ne. “We are proud to offer our guests a perfect balance of relaxation, culinary excellence, and eco-friendly practices, ensuring an enriching stay for families and individuals alike.”

Radisson Resort Mui Ne Beach Front Pool Villa
Radisson Resort Mui Ne Beach Front Pool Villa

A Seaside Sanctuary in Vietnam
Radisson Resort Mui Ne captivates guests with its stunning beachfront location on Suoi Nuoc Beach, one of the area’s most remarkable stretches of coastline. With direct access to the sand and sea, visitors can swim, stroll, and soak up the tropical sun away from the crowds. Visitors can explore the famous white sand dunes, often nicknamed ‘Vietnam’s mini-Sahara’, or visit Bau Trang and Bau Sen, freshwater lakes known for their seasonal lotus blooms and breathtaking views.

A commitment to sustainability 
The resort demonstrates a strong dedication to sustainability, embracing eco-friendly practices such as harnessing solar-powered energy, implementing robust water conservation measures, and providing guests with delicious organic dining options from locally sourced ingredients. Drinking water is bottled directly at the resort to minimize environmental impact. Highlighting Vietnam’s position as the world’s second-largest coffee producer, the resort proudly sources all coffee locally. Additionally, most of the products, from fresh vegetables to seafood and meats, are responsibly sourced from within Vietnam, supporting local communities and reducing the resort’s ecological footprint.

Radisson Resort Mui Ne Dunes Restaurant Terrace
Radisson Resort Mui Ne Dunes Restaurant Terrace

A culinary and adventure journey

Guests are invited to go on an extraordinary culinary journey, showcasing diverse dining experiences emphasizing farm-to-table freshness and authentic regional specialties. From sustainably sourced seafood to traditional Vietnamese dishes, each offering is thoughtfully curated to highlight the authenticity, freshness, health benefits, superior quality, and rich flavors unique to Vietnam. Every dish strikes a harmonious balance, reflecting the culinary philosophy of balance and harmony inherent in Asian cuisine, yin and yang, sweet and salty, fresh and fermented, and cooling and warming, the culinary creations represent the unwavering passion and dedication to bringing guests the finest Vietnamese gastronomy.

Adventure-seekers can also explore thrilling off-property experiences, including kayaking, sand surfing, kite surfing, and hiking. Carefully curated Instagram-worthy spots further enhance the allure, capturing the enchanting landscapes and the unforgettable charm of Mui Ne.

Radisson Resort Mui Ne Bedroom Beach Front Pool Villa
Radisson Resort Mui Ne Bedroom Beach Front Pool Villa

Exploring hidden gems 

The surrounding region is a treasure trove of natural and cultural attractions. From the picturesque white and red sand dunes to local wonders such as the Fish Sauce Museum, Ta Cu Mountain, Thuy Tu Temple, Po Sah Inu Towers, and Ke Ga Lighthouse; every excursion reveals a new chapter of Vietnam’s rich heritage. Mui Ne is also renowned as a top destination for kitesurfing and windsurfing.

Radisson Resort Mui Ne is conveniently situated just three hours by car from Tan Son Nhat International Airport (SGN) in Ho Chi Minh City, making it an easy escape from the city for domestic and international visitors.

Reflecting on the Group’s growing presence in the region, Tim Cordon, Chief Operating Officer, Middle East, Africa & Southeast Asia Pacific. Radisson Hotel Group, added, “Our expansion in Vietnam with Radisson Resort Mui Ne marks an exciting milestone. This opening not only enhances our portfolio in the region but also reinforces our commitment to delivering exceptional experiences in destinations that boast natural beauty and rich cultural heritage.”

For more information or to book, click here. 

Download high-resolution pictures here.

RADISSON HOTEL GROUP 

Radisson Hotel Group is a rapidly expanding international hotel group, operating in EMEA and APAC with over 1,520 hotels in operation and under development in +100 countries. The Group’s overarching brand promise is Every Moment Matters with a signature Yes I Can! service ethos. 

The Radisson family of brands portfolio includes Radisson Collection, art’otel, Radisson Blu, Radisson, Radisson RED, Radisson Individuals, Park Plaza, Park Inn by Radisson, Country Inn & Suites by Radisson, and Prize by Radisson brought together under one commercial umbrella brand Radisson Hotels.  

Radisson Rewards is Radisson Hotel Group’s loyalty program, which delivers an elevated experience that makes Every Moment Matter, counting more than 20 million members. As the most streamlined program in the sector, members enjoy exceptional advantages and can access their benefits from day one across a wide range of hotels in Europe, Middle East, Africa, and Asia Pacific. 

Radisson Meetings provides tailored solutions for any event or meeting, including hybrid solutions placing guests and their needs at the heart of its offer. Radisson Meetings is built around three strong service commitments: Personal, Professional and Memorable, while delivering on the brilliant basics and being uniquely Carbon Compensated.  

At Radisson Hotel Group we care for people, communities and planet and aim to be Net Zero by 2050 based on the approved Science Based Targets. With unique solutions such as carbon compensated Radisson Meetings, we make sustainable hotel stays easy. To facilitate sustainable travel choices, all our hotels are becoming verified on Hotel Sustainability Basics. 

The health and safety of guests and team members remain a top priority for Radisson Hotel Group. All properties across the Group’s portfolio are subject to health and safety requirements, ensuring we always care for our guests and team members. 

For more information, visit our corporate website. Or connect with Radisson Hotels on: 

LinkedIn | Instagram | X | Facebook | YouTube | TikTok 

ABOUT RADISSON 

Radisson is an upscale hotel brand that offers Scandinavian inspired hospitality, which enables guests to find more harmony in their travel experience. With natural surroundings and unexpected delights, Radisson inspires the art of being in the moment, helping guests find the right balance for their stay and enabling them to switch off and relax. Radisson hotels can be found in leisure destinations, suburban and city settings, and near airports. Guests and professional business partners can enhance their experience with Radisson by participating in Radisson Rewards, an international loyalty program offering exceptional benefits and rewards. 

Radisson is part of the Radisson family of brands, which also includes Radisson Collection, art’otel, Radisson Blu, Radisson RED, Radisson Individuals, Park Plaza, Park Inn by Radisson, Country Inn & Suites by Radisson, and Prize by Radisson brought together under one commercial umbrella brand Radisson Hotels. 

For reservations and more information, visit our website. Or connect with Radisson on: 

LinkedIn | Instagram | X | Facebook | YouTube | TikTok 

LG CNS Brings Smart City Innovation to Hogansville, Georgia

  • Signed contract with the City of Hogansville for the deployment of smart poles and an integrated control system
  • Application of LG CNS’s proprietary smart city platform, Cityhub Building, for system management
  • Installation of IoT features and emergency call buttons to improve citizen convenience and public safety

SEOUL, South Korea, April 17, 2025 /PRNewswire/ — LG CNS, a leading AX (AI Transformation) company in Korea, signed its first official contract with a U.S. government agency to build smart city infrastructure in Hogansville, Georgia. This agreement calls for LG CNS to install smart poles and an integrated control system, leveraging its leadership in AI transformation, to enhance public safety, connectivity, and urban operations in the city. The project begins with the installation of smart poles and related infrastructure in downtown Hogansville and city parks.

AI-generated conceptual image of the LG CNS smart pole to be installed in Hogansville
AI-generated conceptual image of the LG CNS smart pole to be installed in Hogansville

Smart poles add intelligence to a city’s urban infrastructure by combining traditional street and traffic lights with advanced IoT technology. Each pole will be equipped with features such as lighting control, public Wi-Fi, CCTV, and environmental sensors. These capabilities will support real-time monitoring of traffic conditions and public safety, while also collecting valuable urban data. The control system managing these poles will be operated through LG CNS’s proprietary smart city platform, Cityhub Building.

In addition to core IoT features, LG CNS will install electric vehicle chargers, digital signage, and emergency call buttons to the smart poles. These buttons will be connected to emergency services like the local police to enable first responders to act quickly in critical situations. These elements also offer greater convenience for residents and significantly strengthen public safety across the city. LG CNS plans to build on the project by expanding its smart city initiatives to nearby cities in Georgia, including LaGrange and West Point.

Recognized as a leader in smart city innovation, LG CNS brings extensive experience in developing and deploying smart city solutions in Korea and around the world. Among other projects, the company provided design consulting for a major smart city development in Indonesia called Nusantara, which is slated to be that country’s new capital. LG CNS is taking part in two large-scale pilot projects in Korea, including Sejong Smart City, valued at approximately 3.2 trillion Korean won, and the Busan Eco Delta Smart City, valued at around 5.4 trillion won. Both projects are being carried out through consortiums.

“Smart infrastructure is essential to accelerating city development, improving operational efficiency, strengthening public safety, and enhancing the daily lives of residents,” said Shin-Gyoon Hyun, CEO of LG CNS. “LG CNS will work closely with the City of Hogansville, drawing on our proven smart city experience in Korea and across the Asia-Pacific region, to help build a more sustainable and livable urban environment.”

About LG CNS

LG CNS is a leading Korean AX (AI Transformation) company that continues to pioneer various emerging technologies, including AI, cloud computing, big data, and smart engineering, encompassing smart factories, smart cities, and smart logistics, as well as digital marketing. The company also leads the market through innovative system integration (SI) and system management (SM) projects across finance, manufacturing, the public sector, and various other industries. For more information, please visit https://www.lgcns.com.

Loft Logistics Ventures into Malaysia with New Warehouse


SINGAPORE – Media OutReach Newswire – 17 April 2025 – Loft Logistics, a 3PL logistics service provider in Singapore, is proud to announce its business expansion into Malaysia with a new warehouse in Shah Alam, Selangor.

Loft Logistics Shah Alam Warehouse
Loft Logistics Shah Alam Warehouse

Driving Growth in Southeast Asia

This strategic move enhances Loft’s capabilities, providing seamless logistics and fulfilment services that support businesses in both Singapore and Malaysia. Since its inception, Loft Logistics has envisioned a fully owned logistics network that services the Southeast Asia region. Given Malaysia’s close proximity to Singapore, it was the natural choice for the company’s first expansion. Encouraged by strong demand from Singapore-based customers, Loft Logistics is now in a prime position to facilitate cross-border trade.

Comprehensive Fulfillment Services in Malaysia

Loft Malaysia will offer the same services as its Singapore operations, ensuring consistency and efficiency for customers. These services include:

  • A customer control tower that will provide visibility of the inventory flow in both locations
  • Inbound management & quality inspections
  • Warehouse storage space for rent
  • Pick and pack operations
  • Bundling and kitting of items
  • Returns sortation, testing and product quality assessment
  • West Malaysia last-mile delivery (B2B and B2C)

Strategic Location: Shah Alam, Selangor

Shah Alam was chosen for its central location between Port Klang and Kuala Lumpur, with a travel time of approximately 35 minutes to either point. The area is well-connected by major expressways such as the Shah Alam Expressway (KESAS) and the Shah Alam Highway (LKSA), making it an ideal distribution hub for West Malaysia.

At the same time, Loft’s expansion presents a unique opportunity for Singaporean businesses looking to enter the Malaysian market. Key benefits include:

  • Consolidated inventory visibility in both Singapore and Malaysia for better stock allocation.
  • Streamlined cross-border trucking services to optimise inventory distribution between locations.
  • Reduced logistics costs by leveraging a localised fulfilment centre in Malaysia.

Supporting both Malaysian companies expanding into Singapore and Singaporean businesses entering Malaysia, Loft’s new warehouse in Shah Alam plays a key role in facilitating growth across the region. It focuses on improving distribution efficiency, providing scalable storage, and reducing delivery lead times within Malaysia. On top of that, businesses utilising these warehousing services can optimise costs by lowering shipping and import duty expenses.

“Our expansion into Malaysia is our initial step in a broader strategy for South East Asia in supporting local SMEs with an integrated cost effective logistics solution,” said Daryl Chan, Co-founder of Loft Logistics.

Unique Offerings in the Malaysia-Singapore Corridor

Loft provides specialised cross-border logistics services, facilitating operations for businesses trading between Singapore and Malaysia. Its offerings include temperature-controlled storage for sensitive products and end-to-end logistics solutions, covering warehousing to last-mile delivery. With an integrated system for real-time inventory tracking across both countries, businesses can manage their supply chains with greater visibility and efficiency.

Loft’s Next Chapter in Southeast Asia’s Logistics Landscape

With this expansion, Loft continues to provide businesses with the tools and infrastructure needed to scale successfully across borders. Stay tuned for further developments as the company moves forward with logistics network expansion in Southeast Asia.

“We have always been aiming to create a seamless logistics network to support businesses in scaling across borders. This expansion allows us to better serve our customers in the region” said Daryl Chan, Co-founder of Loft Logistics.
Hashtag: #loftlogistics





The issuer is solely responsible for the content of this announcement.

About Loft Logistics

Loft Logistics is a logistics company based in Singapore, specialising in storage solutions and fulfilment services tailored to e-commerce businesses. They provide flexible storage options and tech-enabled solutions to help businesses optimise their supply chains and improve operational efficiency.

Disney+ Coming Soon to Whale TV Models

Whale TV to Bring More Premium Entertainment to Whale TV Users Globally with Disney+ 

AMSTERDAM, April 17, 2025 /PRNewswire/ — Leading independent TV OS maker Whale TV™ and the Walt Disney Company have reached an agreement to bring Disney+ to Whale TV enabled smart TVs. Coming soon, on existing Whale TV devices, users will be able to add Disney+ from the app store and enjoy thousands of hours of premium entertainment content including popular titles such as Moana 2, Mufasa: The Lion King, Marvel Television’s Daredevil: Born Again, Lucasfilm’s Andor and more. On new Whale TV models, Disney+ will be available on the home screen upon startup. 

Disney+ Coming Soon to Whale TV Models
Disney+ Coming Soon to Whale TV Models

“Disney+ is one of the top global streaming services with a massive fandom, and is requested a lot by our users,” said Lucas Huang, VP Content Distribution at Whale TV. “We strive to offer the best of global and local services on our platform, so there is always something to watch for everyone.” 

Through the built-in app store, Whale TV users will soon be able to download the Disney+ app to their device. Users can then sign up through the app or sign in with their existing Disney+ subscription. Eligible consumers who purchase a Whale TV enabled television in Brazil and Panama will also be able to redeem a complimentary 12-month subscription to Disney+*. 

About Whale TV 

Whale TV is an independent TV operating system that makes TVs smart and simple to use. Since its inception in 2011, the company has worked with 400+ TV brands and enables 43.5M monthly active TVs around the world to help consumers discover, find and watch their favorite entertainment. With its easy-to-use TV OS, the company connects consumers, TV brands, content providers and advertisers. Whale TV is headquartered in Singapore and has teams collaborating across the globe to make TV better for everyone. 

About Disney+ 

Disney+ is the dedicated streaming home for movies and shows from Disney, Pixar, Marvel, Star Wars, and National Geographic, along with The Simpsons and much more. In select international markets, it also includes the general entertainment content brand, Star, and in the U.S., eligible bundle subscribers can also access select Hulu and ESPN+ content on Disney+**, including next day TV, Hulu and ESPN Originals, live sports events and studio programming. The direct-to-consumer streaming service from The Walt Disney Company,  Disney+ offers an unmatched collection of exclusive originals, including feature-length films, documentaries, live-action and animated series, and short-form content. With unprecedented access to Disney’s long history of incredible film and television entertainment, Disney+ is also the exclusive streaming home for the newest releases from The Walt Disney Studios. Disney+ is available as a standalone streaming service or as part of bundle offerings in the U.S. that give subscribers access to different combinations of Disney+, Hulu, and ESPN+. For more, visit disneyplus.com, or find the Disney+ app on most mobile and connected TV devices.

*Codes are not transferable and may be redeemed by new and returning Disney+ subscribers. Not a gift card. Valid only for residents within the Promotional Offer Territory, 18 years of age or older. Code entitles the holder to twelve (12)- month subscription of Disney+, which will be credited to your account upon redemption. To redeem, you must sign up using the customized link provided to you. A condition to redemption is that holder must create a new Disney+ account or reactivate an existing Disney+ account with a valid e-mail address and accept, if necessary, the Disney+ Subscriber Agreement. You can find the Disney+ Subscriber Agreement at: https://www.disneyplus.com/en-gb/legal/subscriber-agreement ***. Subscription to Disney+ requires a compatible internet device and internet connection. Code is one-time use only, and non-transferable. Void where prohibited. Cannot be combined with any other offers, coupons, discounts or promotions. Code is not refundable or redeemable for cash or any other goods or services and cannot be sold or transferred, or exchanged or credited towards purchase of other subscriptions, and will not be honored if obtained from any third party.

** ESPN on Disney+ requires a plan that includes ESPN+. Select Hulu content available via Disney+ with valid Hulu and Disney+ subscriptions; additional content only available via Hulu app. 18+ only. App feature, device restrictions, and terms apply.

 

Norgine strengthens rare disease portfolio with acquisition of Theravia

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine’s strategy for sustainable growth, adding a complementary portfolio of rare disease medicines

Transaction further establishes Norgine’s position as a partner of choice for commercialising rare and specialty pharmaceuticals in Europe

PARIS, April 17, 2025 /PRNewswire/ — Norgine and Theravia announced today that they have entered into a definitive agreement under which Norgine will acquire Theravia, an international pharmaceutical company specialising in cutting-edge treatments for patients with rare and debilitating conditions.

Recent deals with Fennec Pharma for PEDMARQSI® and X4 Pharma for mavorixafor demonstrate Norgine’s strong emphasis on driving growth in rare disease and specialty medicines through acquisitions and in-licensing.

Theravia’s innovations have resulted in successful launches of life-saving medications which have changed patient outcomes worldwide. Theravia has several products in the rare disease space, including SIKLOS®, for adults and children with sickle cell disease, and ORPHACOL®, a medicine for adults and children who have a genetic disorder that affects bile production by the liver. These products span both the rare haematology and rare hepatology therapeutic areas and are complementary to Norgine’s existing rare and specialty portfolio. The development of Theravia in the past few years has been supported by its majority shareholder Mérieux Equity Partners, a healthcare dedicated investment firm based in France.

This acquisition is a unique opportunity for Norgine to bolster our growth trajectory, as well as our rare disease portfolio.” said Janneke van der Kamp, Chief Executive Officer, Norgine. “With our strong legacy and proven track record of successfully bringing innovative treatments to patients, we believe we are well placed to ensure the Theravia medicines reach their full potential.”

Franck Hamalian, Chief Executive Officer, Theravia, added: “The joining of our companies brings together the skills, know-how and geographical presence that will create a European-based champion of rare and ultra rare disease. Our combined product portfolios and Norgine’s legacy and experience will enable broader access to medicines for patients with high unmet medical needs.”

With the acquisition of Theravia, Norgine will now have six core products in its rare disease portfolio (PEDMARQSI®, eflornithine, mavorixafor, AGILUS®, SIKLOS® and ORPHACOL®) thereby comprising a franchise of critical scale with the ability to be a key growth driver in the medium-to-long-term.

Norgine looks forward to building on this transaction as we continue to strengthen our platform for future acquisitions and in-licensing opportunities to drive growth.

The transaction remains subject to obtaining customary regulatory approvals from the competent authorities.

Notes

About Theravia
Theravia is an international pharmaceutical laboratory specializing in rare or neglected diseases. Formed through the merger of Addmedica and CTRS, Theravia is dedicated to addressing the unmet medical needs of patients with these challenging conditions.

About SIKLOS®
SIKLOS® is used in adults, adolescents and children over two years of age who have sickle-cell syndrome, a genetic disease where the red blood cells become rigid and sticky and change from being disc-shaped to being crescent-shaped (like a sickle). It is used to prevent recurrent, painful vaso-occlusive crises that happen when blood vessels become blocked by the abnormal red blood cells, restricting the flow of blood to an organ. They can include acute chest syndrome, a life-threatening condition when the patient has sudden chest pain, fever, hard breathing or signs of fluid in the lungs on an X-ray.

SIKLOS® is marketed in 17 countries around the world.

About ORPHACOL®
ORPHACOL® is a medicine containing cholic acid, a substance found in the bile, which is used to digest fats. It is approved in the US and Europe used to treat adults and children from one month of age who have a genetic abnormality that makes them unable to produce bile. The therapy is used in patients who do not have enough of two specific liver enzymes which makes their liver unable to produce enough of the main components of bile, called primary bile acids, such as cholic acid. When these primary bile acids are lacking, the body produces abnormal bile acids instead which can damage the liver, potentially leading to life-threatening liver failure.

ORPHACOL® is marketed in 23 countries around the world.

About PEDMARQSI®
PEDMARQSI® is a novel formulation of anhydrous sodium thiosulfate, specifically developed and manufactured for the prevention of cisplatin-induced hearing loss in patients 1 month to <18 years of age. It is the first and only preventative treatment developed for cisplatin-induced ototoxicity to support children and adolescent patients with localised, non-metastatic solid tumour cancers.

It was granted marketing authorisation by the EMA in May 2023 (under the paediatric-use marketing authorisation (PUMA) programme) and the MHRA in October 2023.

About Mavorixafor
Mavorixafor is a selective CXCR4 receptor antagonist approved in the U.S. and marketed by X4 as XOLREMDI®, an oral, once-daily treatment for patients 12 years of age and older with WHIM syndrome, a rare primary immunodeficiency.

In January 2025, X4 submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for mavorixafor for the treatment of WHIM syndrome, for which it has been granted Orphan Drug Designation by both the EMA and the U.S. Food and Drug Administration.

X4 is also developing the medicine to treat chronic neutropenia (CN) and is currently conducting a global, pivotal Phase 3 clinical trial in certain CN disorders. Norgine has responsibility for commercialisation in Europe, Australia, and New Zealand following regulatory approvals.

About Eflornithine
Eflornithine has been investigated for use as a post maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality therapy. It is a targeted therapy that blocks an enzyme called ornithine decarboxylase (ODC), responsible for producing polyamines, which are important to tumour growth and development.

The medicine is approved by the FDA for a maintenance therapy for high-risk neuroblastoma in adult and pediatric patients. In April 2024, an application for approval was submitted by Norgine for the use of eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. In January 2025, a marketing authorisation application was filed to the European Medicines Agency (EMA) for the medicine in high-risk neuroblastoma (HRNB).

About AGILUS®
AGILUS® is a medicine used to treat malignant hyperthermia (rapid rise in body temperature caused by uncontrolled muscle contractions) in adults and children. Malignant hyperthermia is a serious reaction to certain medicines used for general anaesthesia during surgery or other medical procedures.

AGILUS® is approved for use by the EMA for for the treatment of malignant hyperthermia in adults and children in combination with adequate support measures.

About Mérieux Equity Partners
Founded in 2009, Mérieux Equity Partners (“MxEP”) is a leading European healthcare-specialized investment firm, with two dedicated platforms, Venture Capital and Buyout, supporting companies ranging from start-ups to established leaders. Benefiting from a longstanding expertise and a large network, MxEP invests in companies with ambitious growth projects and transformative products or services in healthcare. MxEP is AMF-accredited and currently manages c.€1.5bn of AuM.

About Norgine
Norgine is a uniquely positioned, specialty pharmaceutical and consumer healthcare company, with over €550 million of annual revenues and a 120-year track record of bringing life-changing products to patients and consumers across our core markets of Western Europe, Australia and New Zealand.

Norgine’s integrated approach – strong commercial capabilities, as well as deep medical, regulatory and clinical expertise, in-house manufacturing, robust supply networks, and best-in-class enabling functions – ensures that Norgine can deliver high-quality, transformative medicines quickly and effectively to over 25 million patients annually.

Norgine is a nimble, innovative, and high-performing company that has been transformed by a relentless focus on operational excellence. This focus will enable us to secure the legacy of more than a century of innovation and doing the right thing by our patients, as we push the boundaries and take strides into therapeutic innovation.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]

  • IFINWIL®: now TGA registered in Australia
  • Children diagnosed with neuroblastoma are on average just 2 years old2
  • The average survival rate of children with HRNB is only 50%2

UXBRIDGE, England, April 17, 2025 /PRNewswire/ — Norgine is pleased to announce that the Australian Therapeutic Goods Administration (TGA) has approved the registration of IFINWIL® (eflornithine) for the treatment of adults and paediatric patients with high-risk neuroblastoma (HRNB), who have responded to prior multiagent, multimodality therapy.1

Neuroblastoma Australia welcomed the news today:

On behalf of all families of children impacted by neuroblastoma, we welcome the TGA’s decision to approve IFINWIL®. We urgently need treatments for children diagnosed with neuroblastoma and this milestone marks a step in the right direction towards a better future for children and their families. We thank the Federal Government for taking action to ensure access and we look forward to continued support for children with aggressive cancers.” said Lucy Jones, CEO Neuroblastoma Australia.

High Risk Neuroblastoma is a rare but aggressive form of cancer, predominantly affecting children and most commonly presenting in the first 5 years of life2. Each year in Australia, approximately 50 children are diagnosed with neuroblastoma, with about half of these cases being classified as high risk neuroblastoma3,4. Neuroblastoma originates in the body’s nerve cells (neuroblasts) and typically presents as a primary tumour in the adrenal glands5. It is considered an aggressive tumour because it often spreads to other parts of the body (metastasizes). In most cases, it has spread by the time it is diagnosed5.

“We are committed to improving the lives of children and their families living with high-risk neuroblastoma” said Gus Rudolph, General Manager, Norgine, Australia. “This rare childhood cancer has devastating consequences for those impacted and while more needs to be done to improve treatment outcomes, we would like to recognise the TGA for their work to-date on this approval. Norgine will continue to engage with the relevant stakeholders to bring IFINWIL® to patients as quickly as possible.”

“This approval, as part of the Project Orbis initiative, represents a vital step forward in ensuring access to innovative cancer treatments for patients around the world,” said Dr. David Gillen, Chief Medical Officer, Norgine. “By working collaboratively with international regulatory partners, we are able to help bring promising therapies to paediatric patients sooner – a goal that is especially important when time is critical. We’re proud to support Project Orbis as we strive to expedite access to high-impact oncology medicines.”

Receiving the TGA approval is an important milestone on the path to realising sustainable and equitable access. IFINWIL® is not currently included on the PBS.

Please refer to the IFINWIL® Consumer Medicines Information (CMI) for full safety information on risks, side effects and precautions including the risk of low red blood cells (anaemia), low neutrophils (blood cells that fight infection), low platelets (clotting cells), increase in liver enzymes, and hearing loss or problems balancing.1

Notes to Editors:

About IFINWIL®

IFINWIL® has been investigated for use as a post maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality therapy.6 IFINWIL® is a therapy that blocks an enzyme called ornithine decarboxylase (ODC) responsible for producing polyamines, which are important to tumour growth and development 7.

For more information on IFINWIL®, find the CMI here: IFINWIL Consumer Medicine Information (CMI) or the Therapeutic Goods Administration at https://www.tga.gov.au/ or speak to your healthcare practitioner.

High-Risk Neuroblastoma (HRNB) Treatment Background

Children diagnosed with HRNB undergo an intense treatment regimen that still leaves them vulnerable to relapse and death.8 Although there have been some improvements in survival, children with high risk neuroblastoma still face a 30% chance of recurrence (relapse) within the first 5 years post maintenance, and have an extremely poor prognosis and low likelihood of long term survival9 (e.g. estimates as low as 15% of patients will live for five years after relapsing).10 Avoiding relapse is key to long-term survival, and until now, there have been no approved therapies for the post maintenance treatment period in major markets outside of the United States11.

About Project Orbis

Project Orbis is an initiative (since May 2019) of the US FDA Oncology Center of Excellence (OCE) and provides a framework for concurrent submission and collaborative review of innovative oncology products among international regulatory authorities. It was created with the overarching goal to speed worldwide patient access to innovative cancer therapies. Project Orbis is coordinated by the FDA, and its partners include United Kingdom Medicines and Healthcare Products regulatory Agency (UK MHRA), Australia Therapeutic Goods Administration (TGA), Canada (Health Canada), Singapore (Health Sciences Authority (HSA), Switzerland (Swissmedic), Brazil (Agência Nacional de Vigilância Sanitária (ANVISA), Israel (Ministry of Health).

In April 2024, Norgine submitted an application for approval of eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This milestone supports Norgine’s efforts to deliver patient access to eflornithine and bring a further treatment option in the field of paediatric oncology.

About Norgine

Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do, and our European experience, fully integrated infrastructure and exceptional partnership approach enable us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped more than 25 million patients around the world in 2022 and generated €530 million in net product sales, a growth of nearly 5% over 2021.

Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

References

  1. Australian Product Information, IFINWIL®: IFINWIL Product Information (PI). Accessed 16.04.25
  2. https://www.neuroblastoma.org.au/about-key-statistics. Accessed 26.03.25
  3. Australian Childhood Cancer Registry, Cancer Council Queensland. Australian Childhood Cancer Statistics Online (1983-2021). CCQ: Brisbane, Australia; October 2024.
  4. ANZCHOG-Position-Statement-Eflornithine-DFMO-use-for-patients-with-high-risk-neuroblastoma-in-Australia-and-New-Zealand-v2.0-23.08.2024.pdf
  5. https://rarediseases.info.nih.gov/diseases/7185/neuroblastoma. Accessed 16.03.25
  6. Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Available from: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov.
  7. Meyskens FL Jr, Gerner EW. Clin Cancer Res. 1999 May;5(5):945-51. 4. Sholler GLS, et al. Sci Rep. 2018 Sep 27;8(1):14445.
  8. Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-57.
  9. Desai A, et al. J Clin Oncol. 2022 Jul; JCO2102478. 2. Lewis EC, et al. Int J Cancer. 2020 Dec;147(11):3152-3159
    Bagatell R, DuBois SG, Naranjo A, et al. Children’s Oncology Group’s 2023 blueprint
  10. London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123:4914-23.
  11. FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA, Accessed 02.04.25